Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Mar 8;12(3):e8541.
doi: 10.1002/ccr3.8541. eCollection 2024 Mar.

Rituximab-induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review

Affiliations
Case Reports

Rituximab-induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review

Leila Ghadirzade Arani et al. Clin Case Rep. .

Abstract

Key clinical message: Rituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab-related cutaneous complications will help them in detection and management.

Abstract: Rituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface. Although it is used as promising treatment for pemphigus, nowadays it is also a new therapy for other autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, and others like non-Hodgkin's lymphoma. Although there is increasing evidence regarding the safety and effectiveness of rituximab in these diseases, many cutaneous adverse effects have been reported. Here, we describe a 48-years-old patient affected with pemphigus vulgaris who developed psoriatic lesions on her on scalp, trunk, and extremities, 4 months after the second course of rituximab.

Keywords: pemphigus; psoriasis; rituximab‐induced psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Multiple scaly erythematous plaques on the abdomen (A, B), extensor surfaces of the lower (C) and upper (D) extremities.
FIGURE 2
FIGURE 2
Photo of patient when she had pemphigus vulgaris; multiple erosions on trunk.

Similar articles

References

    1. Vinay K, Dogra S. Rituximab in pemphigus: road covered and challenges ahead: Indian. Dermatol Online J. 2018;9(6):367‐372. doi:10.4103/idoj.IDOJ_290_18 - DOI - PMC - PubMed
    1. Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol. 2009;27(6):996‐998. - PubMed
    1. Alahmari HS, Alhowaish NY, Omair MA. Rituximab‐induced psoriasis in a patient with granulomatosis with polyangitis treated with adalimumab. Case Rep Rheumatol. 2019;2019:5450863. doi:10.1155/2019/5450863 - DOI - PMC - PubMed
    1. Kim DW, Park SK, Woo SH, Yun SK, Kim HU, Park J. New‐onset psoriasis induced by rituximab therapy for non‐Hodgkin lymphoma in a child. Eur J Dermatol. 2016;26(2):190‐191. - PubMed
    1. Mielke F, Schneider‐Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non‐hodgkin lymphoma. Ann Rheum Dis. 2008;67(7):1056‐1057. doi:10.1136/ard.2007.080929 - DOI - PubMed

Publication types

LinkOut - more resources